Lakewood-Amedex to Showcase Nu-3 Antimicrobial at Investor Forum

The company is currently advancing Nu-3 into Phase 2 clinical trials, targeting a significant global patient population suffering from infected diabetic foot ulcers. Cooper emphasized that the drug’s unique mechanism of action aims to prevent severe complications, including amputations, in cases where conventional treatments may fall short. Lakewood-Amedex, traded on the NASDAQ under the ticker LABT, focuses on its proprietary Bisphosphocin class of antimicrobials. These compounds are engineered to combat broad-spectrum infectious diseases and address the growing threat of antibiotic-resistant bacterial strains such as MRSA and VRE. The presentation is scheduled for 11:30 AM EDT, offering investors a look at the developer's pipeline and its potential for market impact.